Work Here?
Overview
Company Does Not Provide H1B Sponsorship
Earli is developing an early cancer-detection platform that uses programmable genetic constructs, called Synthetic Bioclassifiers, which enter cells and activate only in cancer cells. When activated, these constructs make cancer cells produce a specific protein that is released into the bloodstream, serving as a detectable biomarker for early cancer detection. The approach aims to distinguish cancerous from healthy cells by programming the system to reveal cancer signals, addressing limitations of traditional liquid biopsies. Earli plans to commercialize the diagnostic platform through partnerships with healthcare providers and pharmaceutical companies, with Accenture having invested in the company as part of its growth strategy.
About Earli, Inc.
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$59.5M
Headquarters
San Francisco, California
Founded
2018
People at Earli, Inc.
People at Earli, Inc. who can refer or advise you
Simplify's Take
What believers are saying
- Pet trials validated safety and efficacy in over 15 dogs prior to human trials.
- First human clinical trials for lung cancer began at Australian centers in April 2022.
- Strategic investment from Accenture in August 2024 confirms industry confidence in the platform.
What critics are saying
- FDA may reject trial design due to lack of direct patient benefit within 12 months.
- Competitors like Grail dominate early lung cancer detection with FDA-approved tests.
- Species-specific transcription factor mismatch could prevent construct activation in human cancer cells.
What makes Earli, Inc. unique
- Earli uses programmable genetic constructs that turn on exclusively in cancer cells.
- The platform forces cancer to produce synthetic biomarkers detectable in blood and PET scans.
- Earli replaces chemistry with biology for massive signal amplification and targeted tumor destruction.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$59.5M
Above
Industry Average
Funded Over
2 Rounds
Andreessen Horowitz
Menlo VenturesIndustry standards
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 0%2 year growth
↑ 0%Earli, a startup founded by Cyriac Roeding, Dr. David Suhy, and the late Dr. Sanjiv Sam Gambhir, has raised $60 million to advance its cutting-edge cancer detection and treatment technology. The company engineers synthetic biomarkers within cancer cells, enabling earlier and more accurate detection and treatment. Following six years of research, Earli is preparing for human clinical trials, starting with lung cancer, and aims to expand its platform to other cancer types.
GLIN Impact Capital 有限責任事業組合のプレスリリース（2024年10月31日 12時10分）GLIN Impact Capital、がんの早期検出と即時治療につながる技術を開発する米Earliに出資
Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company.
Earli, the company pioneering a new approach to cancer diagnostics by forcing cancer cells to produce synthetic biomarkers, announced today that Maggie Louie accepted the roll of Vice President of Biology.
When Shereen Asad joined Earli as its sixth employee in 2019, her job description didn’t exactly say anything about selling human blood samples.
Earli, Inc. is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Earli, Inc.
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$59.5M
Headquarters
San Francisco, California
Founded
2018
Earli, Inc. is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today